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ABSTRACT 
Purpose. The current manuscript reviews approaches for phenotyping central 
sensitization (CS).  
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Methods.  The manuscript covers the concept of diagnostic phenotyping, use of 
endophenotypes, biomarkers, and symptom clusters. Specifically, the components of CS 
that include general sensory sensitivity (assessed by quantitative sensory testing) and a 
symptom cluster denoting sleep difficulties, pain, affect, cognitive difficulties, and low 
energy (S.P.A.C.E.).   
Results. Each of the assessment domains are described with reference to CS and their 
presence in chronic overlapping pain conditions (COPCs) - conditions likely influenced 
by CS.  
Conclusions.  COPCs likely represent clinical diagnostic phenotypes of CS.  
Components of CS can also be assessed using QST or self-report instruments designed 
to assess single elements of CS or more general composite indices.  Introduction 
Central Sensitization (CS) is a multifaceted spinal and cortical process by which 
the central nervous system (CNS) amplifies nociceptive sensory stimuli, which may then 
be perceived as experiences of unpleasantness, threat or pain.  This special issue has 
combined decades of research to shed light on the mechanisms of this process. While 
CS requires multiple processes to occur, the clinical phenotype is an individual who 
presents with unpleasant sensory experiences disproportionate to any observable 
peripheral cause.  The International Association for the Study of Pain (I.A.S.P.) defines 
CS as “Increased responsiveness of nociceptive neurons in the central nervous system 
to their normal or subthreshold afferent input” (IASP, 2015).  CS can be inferred clinically 
from the presence of allodynia and hyperalgesia. In addition to these markers derived 
from quantitative sensory testing (QST), there may be other indices suggestive of CS 
(Nijs et al., 2014). This article provides additional insights into the clinical characteristics 
of individuals suspected of experiencing CS.  
 
Clinical Characterization: Phenotyping, Biomarkers, and Symptoms 
 A phenotype refers to the composite of one’s observable traits or characteristics 
resulting from an interaction between an individual’s genetic code, in combination with 
influences from the environment.  In practice, clinical phenotypes are often just the 
diagnostic label for a given disease [e.g., Diagnositic and Statistical Manual for Mental 
Disorders (DSM) or International Classification of Diseases (ICD) code].  Such clinical 
phenotypes tend to be defined by expert consensus and often incorporate multiple 
symptoms rather than reflecting discrete or unique pathology.  Due to their breadth, 
diagnostic labels are often less than optimal phenotypes for genetic studies (Hall & 
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Smoller, 2010; Tsuang, 2001).    
 An alternative to using diagnostic labels as phenotypes is the use of more 
genetically informative alternative phenotypes, of which there are three types: (a) 
component phenotypes, (b) intermediate phenotypes, and (c) covariates (Szatmari et al., 
2007). The component phenotype refers to a cardinal symptom or dimension of a 
disorder [e.g., hallucinations in schizophrenia,(Szatmari et al., 2007) widespread pain in 
fibromyalgia (Wolfe et al., 2010)].  To be genetically informative, the component 
symptom should only be found in affected individuals. Intermediate phenotypes occur 
with greater intensity in affected family members than unaffected family members, but 
family members (affected or unaffected) should exhibit the trait more than in the general 
population. Of note, given that the trait occurs in both affected and unaffected family 
members, it cannot be a defining feature of the disorder, like the component phenotype. 
An intermediate phenotype is analogous to the concept of an “endophenotype” and can 
include biochemical, physiological, behavioral, cognitive, and self-reported forms of data. 
Examples of intermediate phenotypes include oculomotor function in schizophrenia 
(Gottesman & Gould, 2003) and affective vulnerability in Temporomandibular Joint 
Disorders (Diatchenko, Nackley, Slade, Fillingim, & Maixner, 2006).  Finally, covariates 
act as moderators defining sub-groups in which the linkage between genetics and the 
disorder may be stronger or weaker depending upon the covariate (e.g., groups with 
early life exposure to pain may be more vulnerable to developing fibromyalgia;  (Low & 
Schweinhardt, 2012)).  
While the intent of identifying phenotypes is to help link observable 
characteristics to genetic markers, much of what has been called phenotyping has never 
actually been validated as having clear links to genetics (e.g., the literature on initial 
smoking risk factors; (Audrain-McGovern, Nigg, & Perkins, 2009).  Thus, using the term 
“phenotyping” may simply reflect a clinical feature that appears to be related to a 
condition but fails to demonstrate genetic linkage.  Such clinical features may simply be 
medical symptoms associated with a diagnostic label or mechanism.   
Often confused with phenotypes is the concept of a biomarker. Biomarkers can 
also be used to characterize a disorder and can be defined broadly as any interaction 
between a biological system and potential hazard that can be reproducibly measured 
(Strimbu & Tavel, 2010). Biomarkers can be functional, physiological, biochemical or 
molecular, but unlike phenotypes, may or may not have genetic influences and can tend 
to be state-dependent phenomena (Beauchaine & Constantino, 2017). Blood pressure is 
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a good example of a biomarker associated with the clinical phenomena of hypertension.  
 Central sensitization, as defined by Woolf (Latremoliere & Woolf, 2009; Woolf, 
2011), has been translated into clinical diagnostic criteria by Nijs and colleagues (Nijs et 
al., 2014). Summarizing this approach for identifying CS, the pain complaint cannot be 
due to neuropathic pain (e.g., lesions, neuropathy, diseases of the nervous system) or 
described as such (e.g., shooting, burning pricking pain) and not due to nociceptive or 
inflammatory processes (e.g., pain proportional to injury or identifiable inflammatory 
processes). In addition, there needs to be evidence of widespread pain (i.e., not just the 
localized complaint), hypersensitivity to sensory processes in general (e.g., sensitivity to 
light, sound, touch, odors etc.), and symptoms that are both products and contributors to 
the construct of “mental load” (e.g., sleep problems, pain intensity, affective lability, 
cognitive difficulties, and lack of energy/fatigue).  See Table 1 for a summary of Nils et 
al.’s approach to clinically identifying patients experiencing CS.  Based upon this 
conceptualization, the clinical characterization of CS appears to involve a combination of 
candidate phenotypes, biomarkers, and medical symptoms.  
 
Chronic Overlapping Pain Conditions (C.O.P.C.s): The Diagnostic Phenotypes of 
CS 
Of the 100 million individuals who suffer with chronic pain, a sizable percentage, 
mostly women, will suffer from multiple chronic pain conditions simultaneously [i.e., 
COPCs; (Committee on Advancing Pain Research, Education, & Institute of, 2011; 
Maixner, Fillingim, Williams, Smith, & Slade, 2016; Veasley et al., 2015)].  The concept 
of coexisting pain conditions has been recognized by the National Institutes of Health 
(NIH) as a set of disorders that may share a common mechanism (e.g., CS) and 
includes, but should not be limited to, temporomandibular disorders (TMD), fibromyalgia 
(FM), irritable bowel syndrome (IBS), vulvodynia (VVD), myalgic 
encephalomyelitis/chronic fatigue syndrome (ME/CFS), interstitial cystitis/painful bladder 
syndrome (IC/PBS), endometriosis (ENDO), chronic tension-type headache (CTTH), 
migraine headache (MI), and chronic lower back pain (CLBP). Thus, despite being 
diagnosed with each condition separately, the problem may not be with the specific 
presenting complaint but with a common mechanism that amplifies peripheral input from 
multiple bodily locations so as to produce centrally augmented pain [i.e., CS; (Clauw, 
2014; Maixner et al., 2016)]. For example, a patient with both IBS and TMD would likely 
be seen by a Gastroenterologist focused upon identifying pathology in the gut as well as 
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a Dentist focused upon identifying pathology in the jaw. In practice, neither practitioner 
would be likely to suspect a common underlying mechanism such as aberrant central 
pain processing. Instead, treatment would likely focus on “correcting” the peripheral or 
anatomical source of each pain complaint - an approach which is not likely to address 
the common underlying etiology of the conditions (Maixner et al., 2016; Williams & 
Clauw, 2009).  Given, the COPCs are suspected of being diagnostic manifestations of 
CS, comparisons of COPCs with other forms of chronic pain may provide valuable 
insights into pragmatic clinical indices of CS.     
Generalized Sensory Hypersensitivity 
One feature of CS that has been explored in the context of COPCs is the concept 
of generalized sensory hypersensitivity. For example, in FM, the cardinal symptom is 
widespread pain and tenderness upon touch.  Upon further assessment however, such 
individuals also tend to report hypersensitivity to other sensory modalities including 
auditory, olfactory, and visual stimuli (Geisser et al., 2008; Wilbarger & Cook, 2011). 
This generalized sensory hypersensitivity has been documented in other COPCs such 
as migraine (Friedman & De ver Dye, 2009; Goadsby et al., 2017; Main, Dowson, & 
Gross, 1997), IBS (Berman et al., 2002; Blomhoff, Jacobsen, Spetalen, Dahm, & Malt, 
2000), and TMD (Hollins et al., 2009).  Generalized sensory hypersensitivity has been 
associated with activation of a cortical network composed of the anterior cingulate, the 
insula, and the prefrontal cortex (Pujol et al., 2014). The function of this network is not 
unique to pain but appears to have the more general function of extracting salient 
sensory stimuli for subsequent higher-order neural processing (Iannetti & Mouraux, 
2010; Schmidt-Wilcke et al., 2014). The means by which this network determines 
salience appears to be based upon the following factors: (1) stimulus novelty, (2) 
sharpness of the stimulus onset, (3) stimulus deviance, and (4) stimulus intensity in 
contrast to less relevant background stimuli (Legrain, Iannetti, Plaghki, & Mouraux, 
2011).   
While clinically it would be difficult to assess and document these cortical events 
using imaging techniques, there are methods from quantitative sensory testing (QST) 
and self-report inventories that can assist in documenting the presence of generalized 
sensory hypersensitivity in clinical settings. 
Quantitative Sensory Testing (QST) assesses psychophysiological mechanisms 
thought to be associated with CS.  Such mechanisms include sensitivity to non-painful 
stimuli (e.g., allodynia), generalized increased pain in response to previously painful 
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stimuli (e.g., hyperalgesia), indices of centrally-mediated pain facilitation (e.g., temporal 
summation), and indices of centrally-mediated pathology in pain inhibitory mechanisms 
(e.g., conditioned pain modulation).  
 Allodynia refers to the experience of pain resulting from traditionally non-painful 
stimuli. For example, someone with CS might experience pain in response to a light 
stroke of a feather or brush. Often the standardized assessment of allodynia utilizes 
monofilaments or exposure to light brush strokes (Maracle et al., 2017). Many of the 
COPCs exhibit allodynia including fibromyalgia (Eken et al., 2017), TMD (Ernberg, 
Hedenberg-Magnusson, Alstergren, Lundeberg, & Kopp, 1999), migraine (Tietjen et al., 
2009), and chronic fatigue (Yasui et al., 2014).  In general, allodynia may be a by-
product of the CS concept of “mental load” (Crettaz et al., 2013).   
Hyperalgesia is typically assessed by identifying pain thresholds in individuals 
using standardized stimuli facilitated by pressure devices such as algometers, ischemic 
cuff algometry, or computerized mechanical testing devices such as the Multimodal 
Automated Sensory Testing (MAST) System [AMI, Ann Arbor, MI 
https://www.arbormedicalinnovations.com/] (Harte et al.; Harte et al.; Henry et al.; Schrepf et 
al.; Wasserman et al., 2015) - an automated QST platform.  In patients presenting with a 
localized pain complaint, increased pain sensitivity at remote or unaffected body areas is 
strongly suggestive of central pain mechanisms and is a common feature of the COPCs 
(Berkley, Cason, Jacobs, Bradshaw, & Wood, 2001; Chaves et al., 2016; Janig, 2015; 
Jayaram et al., 2015; McAllister, McGinty, Resuehr, & Berkley, 2009; Scheich et al., 
2017; Toriyama, Horiuchi, & Hongo, 2017).  
Temporal Summation and its associated metric of windup, is a marker of CNS 
facilitation of pain perception. Technically, it is an increase in pain perception following 
repeated painful stimulation at a constant stimulus intensity. For example, a 256 mN 
pinprick stimulus can be applied once to the forearm or hand, followed by a train of 10 
identical stimuli (1 Hz).  Comparison of the original single pinprick stimuli with the ratings 
after repeated stimulation is used to calculate a wind-up ratio (WUR).  A WUR >1 
indicates temporal summation (Rolke et al., 2006). The presence of windup has long 
been proposed as a feature of central sensitization (Nijs et al., 2014; Woolf, 2011) and 
has been identified in many COPCs [e.g., FM (Price et al., 2002), including TMD 
(Maixner, Fillingim, Sigurdsson, Kincaid, & Silva, 1998), LBP (Tesarz, Eich, Treede, & 
Gerhardt, 2016), endometriosis (Napadow et al., 2012), and IBS (Zhou, Price, Callam, 
Woodruff, & Verne, 2011)]. 
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 QST may not be feasible in all clinical settings, so self-reported sensory 
hypersensitivity may also be used to document this phenomena. One such measure is 
the Sensory Hypersensitivity Scale (SHS)(Dixon et al., 2016).  The SHS is a 25-item 
measure that assesses both general hypersensitivity as well as modality-specific 
sensitivity (e.g., touch taste, auditory).  This instrument demonstrated modest 
associations with three modalities of QST (i.e., heat threshold and tolerance, and cold 
tolerance), and weaker relationships with psychiatric constructs such as depressive 
symptoms and anxiety in a mixed chronic pain and healthy sample. Individuals with FM 
scored higher on this measure than did individuals with low back pain, osteoarthritis or 
healthy controls, thus supporting its construct validity as a measure of sensory 
hypersensitivity (a component of CS).   
 
Symptom Clusters 
 Patients and clinicians may perceive symptoms as arising independently when in 
fact, they may be interacting synergistically (Aktas, Walsh, & Rybicki, 2010).  Such an 
observation has given rise to the study of symptom clusters (Miaskowski, Dodd, & Lee, 
2004)   A common symptom cluster observed within the context of primary care  is 
composed of sleep disturbance, pain, anxiety, depression, and low energy/fatigue 
(SPADE) (Davis, Kroenke, Monahan, Kean, & Stump, 2016).  In this  study of 250 
patients with musculoskeletal pain, only 9.6% were monosymptomatic while 20% of the 
sample had all 5 symptoms in the SPADE cluster. Clearly most of the sample was 
polysymptomatic. The study went on to demonstrate significant associations between 
the number of symptoms and greater functional impairment within the domains of 
general health, physical and mental functioning, social functioning, and health-related 
disability.  
A similar symptom cluster has attracted attention within the oncology literature. 
This cluster, composed of 3 of the SPADE elements, includes pain, sleep insufficiency, 
and fatigue. Being one of the most common combined symptom presentations, this 
cluster is similarly associated with poorer outcomes and poorer functional status in 
oncology patients (Dodd, Miaskowski, & Paul, 2001) and is thought to be associated with 
an underlying inflammatory mechanism (C. S. Cleeland et al., 2003).   
Potentially related to the symptom cluster seen in oncology, “Sickness Behavior” 
is a construct translated from the animal literature describing a coordinated set of 
symptoms elicited by pro-inflammatory cytokines, tumor necrosis factor alpha, 
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interleukin-6, and interleukin 1-beta (Shattuck & Muehlenbein, 2016). The effect in 
animals of such activation is to alter the normal homeostatic condition, so as to cause 
fever, lose appetite, and lose weight. It also causes symptoms similar to those defined 
above, including sleep disturbance, fatigue, altered affect, and increased pain sensitivity 
(Tizard, 2008). Early on, it was observed that sick animals tended to exhibit these 
symptoms, and as such, it was thought to represent weakness or illness. Later studies 
suggested that rather than being a by-product of illness, these symptoms might 
represent an adaptive physiological response designed to enhance the animal’s chances 
of recovery and survival. For example, increased pain sensitivity and fatigue could limit 
hunting and mating, thus conserving energy to fight infection or recover from injury. 
Studies in humans have identified the same sickness behavior symptom cluster  with the 
addition of cognitive disturbances (e.g., memory) (Shattuck & Muehlenbein, 2016), again 
with the potential role of adaptive functioning to conserve resources.  
Whether inflammation is required (as in the sickness behavior model) or not (as 
in the SPADE and some cancer examples), there is remarkable similarity in these 
symptom clusters suggestive of a common mechanism representing a state of “general 
unwellness.” A symptom cluster commonly identified in COPCs includes Sleep 
disturbance, Pain of a widespread distribution, Affective perturbation, Cognitive 
disturbance, and Energy deficit (fatigue). The acronym S.P.A.C.E. can be used to 
remember the elements of this cluster.  S.P.A.C.E. is very similar to SPADE except that 
it adds the construct of cognitive difficulties given the importance of this symptom to 
human sickness behavior model.  In a recent longitudinal study using environmental 
momentary assessment of dyscognition, pain, mood, and fatigue, a lagged relationship 
was identified amongst symptoms, suggesting that dyscognition may actually precede or 
trigger the rest of the symptom cluster (Kratz, Murphy, & Braley, 2017). These results 
underscore the importance of including cognitive problems in a symptom cluster for CS.  
Thus, the presence of S.P.A.C.E. may reflect a state of general unwellness. Perhaps this 
perturbed state is perceived as threatening and gives rise to the sensory hypervigilance 
described above.  Clinically, S.P.A.C.E. can be assessed using a number of instruments 
which will be reviewed next.  
 Sleep.  Disturbances in sleep are common in the context of chronic pain and can 
manifest as problems with falling asleep, staying asleep and early morning awakening.  
Brief instruments for assessing sleep quality and disturbances can be obtained through 
the Patient Reported Outcomes Measurement Information System (PROMIS) 
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administration and information website, AssessmentCenterTM. (Cella et al., 2010). Other 
measures of sleep disturbances that have been used in the assessment of COPCs 
include the Medical Outcomes Study (MOS) sleep scale (Allen, Kosinski, Hill-Zabala, & 
Calloway, 2009) and the Pittsburg Sleep Quality Index [PSQI; (Buysse, Reynolds, Monk, 
Berman, & Kupfer, 1989)].  Sleep duration may not have to be disturbed to impact 
wellness.  It is not uncommon for some patients to report getting a sufficient quantity of 
sleep only to experience that sleep as unrefreshing or non-restorative. Non-restorative 
sleep has been associated with reduced short-wave sleep and abnormal α-rhythms, 
suggestive of wakefulness during non-REM (rapid eye movement) sleep (Choy, 2015). 
This latter from of sleep problem may be the more relevant in the context of COPCs and 
CS (Calhoun, Ford, Finkel, Kahn, & Mann, 2006; Choy, 2015; Tu, Heitkemper, Jarrett, & 
Buchanan, 2017). A measure that captures some of these non-restorative features of 
sleep is the PROMIS measure of sleep-related impairment (Yu et al., 2011).    
 Clinical Pain.  The most common approach to assessing pain is through the use 
of visual analogue scales (VAS), numeric rating scales (NRS) or a “faces” approach (by 
choosing from a range of smiling and frowning faces) (Jensen & Karoly, 2011a).  Pain 
intensity, however, is not unique to CS, and pain intensity alone may not differentiate 
individuals with COPCs from individuals with other forms of chronic pain.  For example, 
in a study comparing pain characteristics of patients with fibromyalgia versus rheumatoid 
arthritis, pain intensity did not differ on a 0-100 VAS (i.e., 61 vs 59 respectively) (Leavitt, 
Katz, Golden, Glickman, & Layfer, 1986). Despite pain intensity failing to distinguish 
these conditions, other aspects of pain did appear distinguishing, such as the quality of 
pain, its distribution (e.g., how wide-spread it was), and its temporality (e.g., constant vs. 
intermittent). Thus in the context COPCs and CS, assessing these other aspects may be 
important (Spiegel et al., 2010). Perhaps most important for CS is the concept of 
widespread pain distribution, which is often captured using a body map. Many of the 
standardized pain assessment tools include a body map, along with measures of pain 
intensity, such as the Brief Pain Inventory [BPI; (C. Cleeland, 2009)] or qualitative 
descriptors such as the  McGill Pain Questionnaire [MPQ; (Melzack, 1975)] and the 
painDETECT.(Freynhagen, Baron, Gockel, & Tolle, 2006a)  In a study of over 400 
individuals with urologic chronic pelvic pain syndrome (UCPPS), only 25% indicated pain 
on a body map as being localized to the pelvic region.  In this study, 75% reported pain 
beyond the pelvic region, with 38% reporting pain in more than 3 sites simultaneously. 
Those with broader pain distributions demonstrated significantly poorer scores on the 
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other elements of the SPACE symptom cluster (Lai et al., 2017).  Similar findings have 
been reported in the context of TMD (Slade et al., 2013) and FM (Cassisi et al., 2014).   
Affect.  By definition, pain of all types is both a sensory phenomenon as well as 
an emotional one (IASP, 2015). This has been supported empirically using neuroimaging 
techniques, which show that chronic pain in particular is represented by cortical 
activations within emotional regions more so than in sensory regions (Apkarian, 
Bushnell, Treede, & Zubieta, 2005). The three emotions that are most commonly 
associated with chronic pain are depressed mood, anxiety, and anger. These emotions 
are in turn associated with reduced pain thresholds, reduced pain tolerances, and 
increased reported pain intensity (Tang et al., 2008; van Middendorp, Lumley, Jacobs, 
Bijlsma, & Geenen, 2010; Wagner, Koschke, Leuf, Schlosser, & Bar, 2009). Depressed 
affect can be assessed using a variety of instruments including the Beck Depression 
Inventory-II (BDI-II; (Beck, Steer, Ball, & Ranieri, 1996; Beck, Steer, & Garbin, 1988), the 
Center for Epidemiological Studies Depression Scale [CESD, CESD-R; (Eaton, 
Muntaner, Smith, Tien, & Ybarra, 2004; Radloff, 1977)] or the Patient Health 
Questionnaire 9 (PHQ-9) (Kroenke, Spitzer, & Williams, 2001)).  Two measures of 
anxiety include the State-Trait Anxiety Inventory [STAI; (Spielberger, Gorsuch, Lushene, 
& Vagg, 1983)] or the General Anxiety Disorder-7 [GAD-7; (Spitzer, Kroenke, Williams, & 
Lowe, 2006)].  Some measures, such as the Hospital Anxiety and Depression Scale 
[HADS; (Snaith, 2003)] assess both constructs.  Scoring of these instruments can reveal 
either a probable diagnosis of an affective disorder or a continuous measure of negative 
affect.  Other measures of negative affect (i.e., not diagnostic of disorders) include the 
PROMIS negative emotions scales (e.g., depressed affect, anxious affect, and anger) 
(Cella et al., 2010) and the Positive and Negative Affect Scale  [PANAS; (Watson, Clark, 
& Tellegen, 1988)].  Currently more studies are needed to identify if there are unique 
affective characteristics that differentiate COPCs (and by implication CS) from other 
forms of chronic pain. As mentioned previously, the study of UCPPS patients 
demonstrated that greater wide-spreadedness of pain was associated with worse 
depressive and anxiety symptoms (as measured by the HADS) and worse mental health 
overall (as measured by the SF12) for both males and females (Lai et al., 2017).   
Cognition. Perhaps one of the most under-assessed symptoms in the S.P.A.C.E. 
cluster is cognition. In an exercise to identify relevant assessment domains for 
fibromyalgia, the Outcome Measures in Rheumatology clinical Trials network 
(OMERACT) conducted two Delphi studies; one with providers and one with patients. 
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While there was agreement between the groups as to the importance of including 
symptoms such as pain, fatigue, and sleep, the patients rated cognitive problems as 
being far more important than did clinicians (Arnold et al., 2008; Mease et al., 2008; 
Mease et al., 2005).   
To assess perceived cognitive difficulties across several dimensions, the Multiple 
Ability Self-Report Questionnaire [MASQ; (Seidenberg, Haltiner, Taylor, Hermann, & 
Wyler, 1994)] has been used with FM samples (Williams & Arnold, 2011; Williams, 
Clauw, & Glass, 2011) and is able to capture  perceived cognitive difficulties across 
language ability, visual-perceptual ability, verbal memory, visual memory, and 
attention/concentration.  A second shorter measure, using items from the NIH PROMIS 
item banks is called the Multidimensional Inventory of Subjective Cognitive Impairment 
[MISCI; (Kratz, Schilling, Goesling, & Williams, 2015)]. This 10-item inventory, which 
provides indices for cognitive concerns in the areas of mental clarity, memory, 
attention/concentration, executive functioning, and language, is highly correlated (r = 
0.82) with the lengthier MASQ, and was validated on a sample of FM patients. 
Energy. Fatigue may be as concerning to patients as pain and has become a 
research priority in painful conditions, including IBS (Lackner, Gudleski, Dimuro, Keefer, 
& Brenner, 2013), TMS (Robinson, Durham, & Newton, 2016), FM (Dailey, Keffala, & 
Sluka, 2015), and migraine (Lau, Lin, Chen, Wang, & Kao, 2015).  The assessment of 
fatigue is challenging, given the need to distinguish qualitative aspects of the experience 
of fatigue; that is, to differentiate normal tiredness that might follow energy exertion from 
the more profound existential weariness that is described by individuals with COPCs 
(Humphrey et al., 2010).  It can also be important to differentiate the experience of 
fatigue from the impact of fatigue (e.g., too fatigued to work, too fatigued to participate in 
activities of daily living etc.). One measure that nicely differentiates the experience of 
fatigue from its impact is the Multidimensional Fatigue Inventory (MFI; (Smets, Garssen, 
Bonke, & De Haes, 1995)). The latter instrument allows for the assessment of general 
fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity.  
PROMIS also offers brief assessments of fatigue experience and interference/impact 
(Cella et al., 2010).  Based upon the PROMIS item–banks, a Fatigue Profile has been 
developed that was specifically validated with a group of individuals with FM  (Kratz, 
Schilling, Goesling, & Williams, 2016).  
 
Associated Domains of Assessment 
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Two additional domains of assessment that may have relevance to CS are 
perceived stress and early life trauma. Nijs et al. highlighted the importance of 
hypersensitivity of senses that are unrelated to the musculoskeletal system.  Included in 
the list of drivers of hypersensitivity are stress and the concept of mental load (Nijs et al., 
2014). When sensory stimuli ascend from the periphery, they must be evaluated by the 
current state of the CNS, which can include stress and negative aspects of mental load.  
Stress is a state-like phenomena with influences on pain perception and other elements 
of CS and can be  assessed with measures such as the Perceived Stress Scale [PSS; 
(Cohen, Kamarck, & Mermelstein, 1983)].  More enduring stressful events, such as early 
life trauma, can influence affect and mental load in a trait-like manner.  A variety of early 
life traumas (e.g., prolonged medical illness, loss of a parent, abuse etc.), and whether 
or not such traumatic events were disclosed to anyone, can be assessed using the 
Childhood and Recent Traumatic Events Scales [CTES/RTES; (Pennebaker & Susman, 
1988)] as a contributor to mental load.   
 
Existing and Future Measures of CS and COPCs 
The Central Sensitization Inventory (CSI) (Neblett et al., 2013)  was developed 
for the expressed purpose of assessing CS-related symptoms and has been mentioned 
frequently throughout this special issue.  The CSI efficiently captures many of the 
domains covered in this article that are conceptually related to CS. For example, the CSI 
includes items associated with medical symptoms such as sleep problems, stress 
(mental load), pain, emotionality, concentration/memory, fatigue, and limited physical 
functioning.  The CSI also includes items associated with general sensory 
hypersensitivity (e.g. sensitivity to bright lights and olfactory stimuli). The CSI is one 
assessment component of the clinical diagnostic algorithm by Nijs and colleagues, 
mentioned earlier in this article, for identifying CS-related pain (Nijs et al., 2014). While 
conceptually strong, future instruments may want to demonstrate stronger empirical 
relationships between self-reported items and QST, neuroimaging markers of CS, and 
S.P.A.C.E.  Such a prospective measure [i.e., the Central Pain Index (CPI)] is currently 
in development [NIH/NIAMS funding (AR070600)].  
The modified ACR 2010 diagnostic criteria for FM can also be used as a proxy 
for assessing CS or centrally augmented pain (Wolfe et al., 2016). When scored as a 
continuous measure rather than a dichotomous diagnosis, the Poly-Symptomatic 
Distress score (PSD) appears to capture important elements of CS.  The PSD is 
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composed of an index of wide-spread pain, and each of the other elements of the 
S.P.A.C.E. symptom cluster. One might predict that peripherally driven interventions 
(e.g., surgery) would be less successful in individuals where CS is driving the pain 
experience. Such a hypothesis is supported by several studies, were higher scores on 
the PSD scale were associated with greater need for opioids and poorer outcomes 
following knee and hip arthroplasty and hysterectomy (As-Sanie et al., 2017; Brummett 
et al., 2015; Janda et al., 2015).  
Another way of assessing CS indirectly is by identifying the presence of COPCs.  
Until recently, there were no diagnostic tools that could capture the presence of all 10 
COPCs using established diagnostic criteria. The NIH Pain Consortium has recently 
championed the development of such a tool using funding with the Office of Research on 
Women’s Health, the Multidisciplinary Approach to the Study of Chronic Pelvic Pain 
(MAPP) and the Orofacial Pain: Prospective Evaluation and Risk Assessment 
(OPPERA) research networks. This new instrument, the “COPC Screener”, will be made 
publically available and will be able to serve as a standardized way of assessing 
individuals suspected of having conditions where CS is the suspected pathophysiologic 
mechanism.  
 
Conclusion 
Central Sensitization likely underlies how normal sensory or mild nociceptive 
stimuli can be amplified by the CNS to produce a profound and prolonged pain 
experience.  Clinically COPCs are the best representations of conditions having CS as a 
primary mechanism.  To comprehensively phenotype the facets of CS in a clinical 
sample, a combination of QST, to identify multi-sensory hypersensitivity, and patient-
reported outcomes of the S.P.A.C.E. symptom cluster (i.e., “unwellness”) can be used. 
(see Table 2) In addition, multi-component self-report instruments such as the CSI or FM 
diagnostic criteria are efficient clinical tools for indexing CS comprehensively.  
 
 
 
   
Table 1. Criteria for the Clinical Classification of Central Sensitization Pain (Nijs et al., 
2014) 
Step 1 Rule out  No history or identification of  lesion or disease 
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Neuropathic Pain of the nervous system    Pain is not neuroanatomically logical  Pain is not described as burning, shooting or 
pricking. 
Step 2 Rule out Nociceptive 
Pain 
Pain will be disproportionate to the extent of injury or 
pathology 
Step 3 At least one of the 
following 
(if Steps 1-3 are 
positive then CS 
present) 
 Bilateral symmetrical pain pattern  Pain varying in anatomical location (i.e., 
traveling) or large neuroanatomically  illogical 
distributions    Widespread pain in all four quadrants of the 
body  Allodynia/hyperalgesia outside the reported 
primary site of pain 
Step 4 General 
hypersensitivity to 
sensory stimuli 
(If Steps 1-2, & 4 are 
positive then CS 
present)  
Can include: mechanical pressure, odors, chemicals, 
cold, heat, electrical stimulation, light, sounds, weather, 
food, stress, emotions, mental load. Can be assessed 
as a score of >= 40 on the CSI. 
 
Table 2.  CS Domains and Sample Self-Reported Assessment Tools  
Domain and 
Instruments 
Purpose Reference 
Chronic Overlapping 
Pain Conditions 
Diagnostic entities with CS being the 
suspected pathophysiological mechanism 
 
CMSI Assesses a subset of the 10 COPCs (Williams & 
Schilling, 2009) 
COPCS Assesses all 10 COPCS (still in beta 
version as of this 
publication) 
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General 
Hypersensitivity 
  
SHS Assesses general and specific sensory 
hypersensitivity 
(Dixon et al., 2016) 
   
S.P.A.C.E. Symptom 
Cluster 
  
MOS Sleep Scale Sleep Problems (Allen et al., 2009) 
PSQI Sleep Problems (Buysse et al., 
1989) 
PROMIS Sleep 
Disturbance 
Sleep Problems (Yu et al., 2011) 
PROMIS Sleep-related 
Impairment 
Non-restorative sleep (Yu et al., 2011) 
VAS, NRS  Pain intensity (Jensen & Karoly, 
2011b)  
MPQ     Pain Quality and intensity (Melzack, 1987) 
BPI Pain distribution and intensity (C. Cleeland, 
2009) 
PainDetect Pain distribution, intensity quality: 
differentiate nociceptive from neuropathic 
(Freynhagen, 
Baron, Gockel, & 
Tolle, 2006b) 
BDI-II Depressive symptomatology (Beck et al., 1996) 
CESD-R Depressive symptomatology (Eaton et al., 2004) 
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PHQ-9 Depressive symptomatology (Kroenke et al., 
2001) 
STAI Anxiety symptoms (Spielberger et al., 
1983) 
GAD-7 Anxiety symptoms (Spitzer et al., 
2006) 
HADS Both anxiety and depressive symptoms (Snaith, 2003) 
PANAS Positive and negative affect (Watson et al., 
1988) 
PROMIS Negative 
Emotions 
Negative emotions (Cella et al., 2010) 
MASQ Perceived cognitive difficulties (Seidenberg et al., 
1994) 
MISCI Perceived cognitive difficulties (Kratz et al., 2015) 
MFI Fatigue experience (Smets et al., 
1995) 
PROMIS Fatigue Fatigue experience and impact (Cella et al., 2010) 
Fatigue Profile Fatigue experience and impact (Kratz et al., 2016) 
   
Supplemental 
Domains 
  
PSS Perceived stress (Cohen et al., 
1983) 
CTES/RTES Early and recent trauma (Pennebaker & 
Susman, 1988) 
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Comprehensive CS 
Instruments 
  
CSI Multiple components of CS (Neblett et al., 
2013) 
Modified FM Criteria Multiple components of central pain (Wolfe et al., 2016) 
 
Note. Complex Medical Symptom Inventory (CMSI); Chronic Overlapping Pain 
Conditions Screener (COPCS); Sensory Hypersensitivity Scale (SHS); Medical 
Outcomes Survey Sleep Scale (MOS sleep Scale); Pittsburgh Sleep Quality Index 
(PSQI); PROMIS Sleep Disturbance Scale; PROMIS Sleep-related impairment scale; 
Visual Analogue Scale (VAS), Numeric Rating Scale (NRS);  
McGill Pain Questionnaire (MPQ); Brief Pain Inventory (BPI); PainDetect; Beck 
Depression Scale-II (BDI-II); Center for Epidemiologic Studies Depression Scale (CESD-
R); Patient Health Questionnaire 9-item Scale (PHQ-9); State Trait Anxiety Inventory 
(STAI); General Anxiety Disorder 7-item Scale (GAD-7); Hospital Anxiety and 
Depression Scale (HADS); Positive and Negative Affect Scale (PANAS); PROMIS 
Negative Emotions Scale; Multiple Abilities Symptom Questionnaire (MASQ); 
Multidimensional Inventory of Subjective Cognitive Impairment (MISCI); 
Multidimensional Fatigue Inventory (MFI); PROMIS Fatigue Scale; Fatigue Profile; 
Perceived Stress Scale (PSS); Childhood/Recent Traumatic Events Scale 
(CTES/RTES); Central Sensitization Index (CSI); Modified ACR2010 FM diagnostic 
Criteria. 
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